ED2 LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN INTYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING
Abstract
Authors
G Goodall WJ Valentine C Townsend R Kotchie S Nielsen K Erny-Albrecht